Three Cancer Drugs Advance Toward Broader EU Use Edited by Joyani Das

https://www.medscape.com/viewarticle/three-cancer-drugs-advance-toward-broader-eu-use-2026a1000pn1?src= Three established cancer therapies — Enhertu (trastuzumab deruxtecan, Daiichi Sankyo Europe), Piqray (alpelisib, Novartis Europharm), and Trodelvy (sacituzumab govitecan, Gilead Sciences) — moved closer to expanded use in the EU after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended extensions of indication for all three at its July 2026 meeting.